PH12014502704A1 - Compounds and compositions for modulating egfr activity - Google Patents

Compounds and compositions for modulating egfr activity

Info

Publication number
PH12014502704A1
PH12014502704A1 PH12014502704A PH12014502704A PH12014502704A1 PH 12014502704 A1 PH12014502704 A1 PH 12014502704A1 PH 12014502704 A PH12014502704 A PH 12014502704A PH 12014502704 A PH12014502704 A PH 12014502704A PH 12014502704 A1 PH12014502704 A1 PH 12014502704A1
Authority
PH
Philippines
Prior art keywords
compounds
egfr activity
compositions
modulating egfr
modulating
Prior art date
Application number
PH12014502704A
Other languages
English (en)
Other versions
PH12014502704B1 (en
Inventor
Lelais Gerald
Epple Robert
Iii Thomas H Marsilje
Michellys Pierre-Yves
Matthew H Mcneill
Long Yun
Lu Wenshuo
Chen Bei
Bursulaya Badry
Jiang Songchun
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54193706&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12014502704(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Irm Llc filed Critical Irm Llc
Publication of PH12014502704A1 publication Critical patent/PH12014502704A1/en
Publication of PH12014502704B1 publication Critical patent/PH12014502704B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
PH12014502704A 2012-06-06 2014-12-03 Compounds and compositions for modulating egfr activity PH12014502704B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1741DE2012 2012-06-06
US201361770752P 2013-02-28 2013-02-28
PCT/US2013/044247 WO2013184757A1 (en) 2012-06-06 2013-06-05 Compounds and compositions for modulating egfr activity

Publications (2)

Publication Number Publication Date
PH12014502704A1 true PH12014502704A1 (en) 2015-02-02
PH12014502704B1 PH12014502704B1 (en) 2015-02-02

Family

ID=54193706

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12014502704A PH12014502704B1 (en) 2012-06-06 2014-12-03 Compounds and compositions for modulating egfr activity

Country Status (42)

Country Link
US (1) US9440957B2 (enExample)
EP (2) EP3257848A1 (enExample)
JP (1) JP6039800B2 (enExample)
KR (1) KR101817829B1 (enExample)
CN (1) CN104379575B (enExample)
AP (1) AP3909A (enExample)
AR (1) AR091368A1 (enExample)
AU (1) AU2013271733B2 (enExample)
BR (1) BR112014030386B1 (enExample)
CA (1) CA2875966C (enExample)
CL (1) CL2014003227A1 (enExample)
CO (1) CO7160047A2 (enExample)
CR (1) CR20140563A (enExample)
CU (1) CU20140139A7 (enExample)
CY (1) CY1119531T1 (enExample)
DK (1) DK2773635T3 (enExample)
DO (1) DOP2014000277A (enExample)
EA (1) EA026269B1 (enExample)
ES (1) ES2645973T3 (enExample)
GE (1) GEP201606555B (enExample)
GT (1) GT201400282A (enExample)
HR (1) HRP20171670T1 (enExample)
HU (1) HUE034759T2 (enExample)
IL (1) IL235974A (enExample)
JO (1) JO3300B1 (enExample)
LT (1) LT2773635T (enExample)
MA (1) MA37739B1 (enExample)
MX (1) MX345630B (enExample)
MY (1) MY165036A (enExample)
NZ (1) NZ627661A (enExample)
PE (1) PE20150726A1 (enExample)
PH (1) PH12014502704B1 (enExample)
PL (1) PL2773635T3 (enExample)
PT (1) PT2773635T (enExample)
RS (1) RS56396B1 (enExample)
SG (1) SG11201407793TA (enExample)
SI (1) SI2773635T1 (enExample)
TN (1) TN2014000487A1 (enExample)
TW (1) TWI650319B (enExample)
UA (1) UA113543C2 (enExample)
UY (1) UY34849A (enExample)
WO (1) WO2013184757A1 (enExample)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106957282B (zh) 2011-12-21 2019-08-30 诺维拉治疗公司 B型肝炎抗病毒剂
CN110507654A (zh) 2012-04-03 2019-11-29 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
AR092270A1 (es) 2012-08-28 2015-04-08 Janssen R&D Ireland Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
EP2890691B1 (en) * 2012-08-31 2018-04-25 Principia Biopharma Inc. Benzimidazole derivatives as itk inhibitors
ES2628953T3 (es) 2013-02-28 2017-08-04 Janssen Sciences Ireland Uc Sulfamoilarilamidas y el uso de las mismas como medicamentos para el tratamiento de la hepatitis B
UY35464A (es) 2013-03-15 2014-10-31 Araxes Pharma Llc Inhibidores covalentes de kras g12c.
MX353412B (es) 2013-04-03 2018-01-10 Janssen Sciences Ireland Uc Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
JP6441315B2 (ja) 2013-05-17 2018-12-19 ヤンセン・サイエンシズ・アイルランド・ユーシー スルファモイルチオフェンアミド誘導体およびｂ型肝炎を治療するための医薬品としてのその使用
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
PL3024819T3 (pl) 2013-07-25 2018-08-31 Janssen Sciences Ireland Uc Pochodne piroloamidowe podstawione glioksamidem i ich zastosowanie jako leków do leczenia wirusowego zapalenia wątroby typu B
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
SG11201602748XA (en) 2013-10-23 2016-05-30 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
WO2015085482A1 (en) * 2013-12-10 2015-06-18 Novartis Ag Egfr inhibitor forms
WO2015081463A1 (en) * 2013-12-02 2015-06-11 Novartis Ag Egfr inhibitor forms
WO2015083059A1 (en) * 2013-12-02 2015-06-11 Novartis Ag Forms of the egfr inhibitor
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
KR20160128305A (ko) 2014-02-05 2016-11-07 노비라 테라퓨틱스, 인코포레이티드 Hbv 감염의 치료를 위한 병용 요법
ES2705401T3 (es) 2014-02-06 2019-03-25 Janssen Sciences Ireland Uc Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la Hepatitis B
WO2015134210A1 (en) * 2014-03-03 2015-09-11 Principia Biopharma, Inc. BENZIMIDAZOLE DERIVATIVES AS RLK and ITK INHIBITORS
CA2936962C (en) 2014-03-14 2024-03-05 Novartis Ag Antibody molecules to lag-3 and uses thereof
KR102409739B1 (ko) * 2014-03-20 2022-06-17 카펠라 테라퓨틱스, 인크. 암 치료용의 ｅｒｂｂ 티로신 키나제 억제제로서의 벤즈이미다졸 유도체
EP3922630A1 (en) * 2014-03-20 2021-12-15 Capella Therapeutics, Inc. Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
WO2015145388A2 (en) 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
BR112017001695A2 (pt) 2014-07-31 2017-11-21 Novartis Ag terapia de combinação
CA2960824A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
EP3662903A3 (en) 2014-10-03 2020-10-14 Novartis AG Combination therapies
US20170304313A1 (en) 2014-10-06 2017-10-26 Novartis Ag Therapeutic Combination For The Treatment Of Cancer
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CA2964367C (en) 2014-10-14 2024-01-30 Novartis Ag Antibody molecules to pd-l1 and uses thereof
HK1247089A1 (zh) 2015-03-10 2018-09-21 Aduro Biotech, Inc. 用於活化“干扰素基因刺激物”依赖性信号传导的组合物和方法
EP3271019A1 (en) 2015-03-19 2018-01-24 Novira Therapeutics Inc. Azocane and azonane derivatives and methods of treating hepatitis b infections
EA201792214A1 (ru) 2015-04-10 2018-01-31 Араксис Фарма Ллк Соединения замещенного хиназолина
JP6789239B2 (ja) 2015-04-15 2020-11-25 アラクセス ファーマ エルエルシー Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法
CN108012529A (zh) * 2015-05-15 2018-05-08 诺华股份有限公司 治疗egfr突变的癌症的方法
EP3297609A1 (en) * 2015-05-22 2018-03-28 Novartis AG Pharmaceutical compositions
CA2987914C (en) * 2015-06-30 2022-09-13 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US20180177872A1 (en) * 2015-07-29 2018-06-28 Yong Jia Combination of PD-1 antagonist with an EGFR inhibitor
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
WO2017019896A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to pd-1
WO2017049069A1 (en) * 2015-09-18 2017-03-23 Merck Patent Gmbh Heteroaryl compounds as irak inhibitors and uses thereof
US10590108B2 (en) 2015-09-23 2020-03-17 Capella Therapeutics, Inc. Benzimidazoles for use in the treatment of cancer and inflammatory diseases
WO2017058915A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356354A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10882847B2 (en) 2015-09-28 2021-01-05 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058768A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10689356B2 (en) 2015-09-28 2020-06-23 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356347A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
JP6845231B2 (ja) 2015-09-29 2021-03-17 ノヴィラ・セラピューティクス・インコーポレイテッド Ｂ型肝炎抗ウイルス薬の結晶形態
BR112018008891A8 (pt) 2015-11-03 2019-02-26 Janssen Biotech Inc anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos
CA3005089A1 (en) 2015-11-16 2017-05-26 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
WO2017175156A1 (en) * 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
WO2017175144A1 (en) 2016-04-08 2017-10-12 Novartis Ag New therapeutic uses
KR20180129943A (ko) 2016-04-15 2018-12-05 노비라 테라퓨틱스, 인코포레이티드 캡시드 조립 억제제를 포함하는 배합물 및 방법
US20170321285A1 (en) * 2016-05-03 2017-11-09 The Texas A&M University System Nlrc5 as a biomarker for cancer patients and a target for cancer therapy
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
CN107663170B (zh) * 2016-07-29 2020-02-11 广东东阳光药业有限公司 制备贝西沙星中间体化合物的方法
CA2939286A1 (en) * 2016-08-17 2018-02-17 Pharmascience Inc. Spirocyclic containing compounds and pharmaceutical uses thereof
JP2019529484A (ja) 2016-09-29 2019-10-17 アラクセス ファーマ エルエルシー Ｋｒａｓ ｇ１２ｃ変異体タンパク質の阻害剤
CN110312711A (zh) 2016-10-07 2019-10-08 亚瑞克西斯制药公司 作为ras抑制剂的杂环化合物及其使用方法
AU2017378320B2 (en) * 2016-12-13 2024-01-04 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating cancers containing fusion genes
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
JP7327802B2 (ja) 2017-01-26 2023-08-16 アラクセス ファーマ エルエルシー 縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
CN106946779A (zh) * 2017-02-13 2017-07-14 广州仁恒医药科技股份有限公司 一种r‑3‑氨基‑六氢氮杂*的制备方法
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
TW201906832A (zh) 2017-05-25 2019-02-16 美商亞瑞克西斯製藥公司 用於癌症治療之化合物及其使用方法
JP2020521740A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー 変異体ｋｒａｓ、ｈｒａｓまたはｎｒａｓの調節因子としてのキナゾリン誘導体
US10745385B2 (en) 2017-05-25 2020-08-18 Araxes Pharma Llc Covalent inhibitors of KRAS
MY204117A (en) 2017-06-22 2024-08-08 Novartis Ag Antibody molecules to cd73 and uses thereof
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
TW201904993A (zh) 2017-06-22 2019-02-01 瑞士商諾華公司 IL-1β 結合抗體之用途
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
RU2020108192A (ru) 2017-08-03 2021-09-03 Новартис Аг Терапевтическая комбинация ингибитора тирозинкиназы egfr третьего поколения и ингибитора raf
AU2018311522A1 (en) 2017-08-03 2020-01-16 Novartis Ag Therapeutic combination of a third generation EGFR tyrosine kinase inhibitor and a cyclin D kinase inhibitor
CN109721605B (zh) * 2017-10-31 2022-03-11 维眸生物科技（上海）有限公司 一种免疫细胞迁徙抑制剂
AU2018375738A1 (en) 2017-11-30 2020-06-11 Novartis Ag BCMA-targeting chimeric antigen receptor, and uses thereof
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
CN111741954B (zh) * 2018-02-21 2024-04-02 勃林格殷格翰国际有限公司 用作egfr抑制剂的新型苯并咪唑化合物及衍生物
EP3765011A1 (en) 2018-03-14 2021-01-20 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
KR20210003801A (ko) 2018-04-18 2021-01-12 노파르티스 아게 Cns 전이의 치료에서 사용하기 위한 나자르티닙
CA3098283C (en) 2018-04-26 2023-05-23 Pfizer Inc. 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
CN118459594A (zh) 2018-06-01 2024-08-09 诺华股份有限公司 针对bcma的结合分子及其用途
BR112021001709A2 (pt) 2018-08-01 2021-05-04 Araxes Pharma Llc compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer
US20220025036A1 (en) 2018-12-21 2022-01-27 Novartis Ag Use of il-1beta binding antibodies
CN109369620B (zh) * 2018-12-22 2020-04-14 山东大学 吡啶类化合物及其制备方法与抗胃癌应用
MA55020A (fr) 2019-02-22 2021-12-29 Janssen Sciences Ireland Unlimited Co Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
CN111747931A (zh) * 2019-03-29 2020-10-09 深圳福沃药业有限公司 用于治疗癌症的氮杂芳环酰胺衍生物
AR119732A1 (es) 2019-05-06 2022-01-05 Janssen Sciences Ireland Unlimited Co Derivados de amida útiles en el tratamiento de la infección por vhb o de enfermedades inducidas por vhb
US20220380382A1 (en) 2019-06-24 2022-12-01 Boehringer Ingelheim International Gmbh New macrocyclic compounds and derivatives as egfr inhibitors
US20220348651A1 (en) 2019-09-18 2022-11-03 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
WO2021072475A1 (en) * 2019-10-15 2021-04-22 Aucentra Therapeutics Pty Ltd Derivatives of 4-(imidazo[1,2-a]pyridin-3-yl)-n-(pyridin-3-yl) pyrimidin-2- amine for treating proliferative diseases and conditions
KR102267662B1 (ko) * 2019-11-19 2021-06-22 한국화학연구원 벤즈아미드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
TW202207933A (zh) 2020-05-08 2022-03-01 瑞士商諾華公司 包含tno155及那紮替尼之藥物組合
KR20210142553A (ko) * 2020-05-18 2021-11-25 웰마커바이오 주식회사 Ron 돌연변이와 관련된 소세포 폐암 예방 또는 치료용 약학 조성물 및 이를 이용한 방법
KR20210142555A (ko) * 2020-05-18 2021-11-25 웰마커바이오 주식회사 Ron 돌연변이와 관련된 췌장암 예방 또는 치료용 약학 조성물 및 이를 이용한 방법
JP2023526443A (ja) * 2020-05-18 2023-06-21 ウェルマーカー バイオ カンパニー リミテッド Ｒｏｎ変異が関与する非小細胞肺がんの予防又は治療用医薬組成物及びその使用方法
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
CN113880804A (zh) * 2020-07-01 2022-01-04 微境生物医药科技(上海)有限公司 新型苯并咪唑化合物
CA3195035A1 (en) * 2020-10-12 2022-04-21 Dana Farber Cancer Institute, Inc. Covalent egfr inhibitors and methods of use thereof
WO2022090481A1 (en) 2020-11-02 2022-05-05 Boehringer Ingelheim International Gmbh Substituted 1h-pyrazolo[4,3-c]pyridines and derivatives as egfr inhibitors
US20240025993A1 (en) 2020-11-06 2024-01-25 Novartis Ag Cd19 binding molecules and uses thereof
JP2024519054A (ja) * 2021-05-17 2024-05-08 エイチケイ イノ．エヌ コーポレーション ベンズアミド誘導体、その調製方法、およびそれを有効成分として含む、がんの予防または治療のための医薬組成物
CN115368378B (zh) * 2021-05-21 2024-11-19 深圳市塔吉瑞生物医药有限公司 取代的大环化合物及包含该化合物的组合物及其用途
EP4355330A1 (en) 2021-06-15 2024-04-24 Genentech, Inc. Egfr inhibitor and perk activator in combination therapy and their use for treating cancer
US20240352021A1 (en) * 2021-10-18 2024-10-24 Dana-Farber Cancer Institute, Inc. Covalent egfr inhibitors and methods of use thereof
KR102572664B1 (ko) * 2022-02-07 2023-08-30 주식회사 인터엠 오디오 클록 조정 및 이를 이용한 네트워크 기반 전관 방송
CA3249080A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab CONDENSED BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR USE IN CANCER TREATMENT
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
US20240116926A1 (en) 2022-04-28 2024-04-11 Astrazeneca Ab Heteroaromatic compounds
IL317645A (en) * 2022-06-14 2025-02-01 Principia Biopharma Inc Methods for preparing tolbrutinib
TW202416963A (zh) * 2022-09-02 2024-05-01 大陸商迪哲（江蘇）醫藥股份有限公司 Ｅｇｆｒ抑制劑及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
MA26659A1 (fr) 1998-08-06 2004-12-20 Pfizer Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
WO2000029574A2 (en) 1998-11-18 2000-05-25 Incyte Pharmaceuticals, Inc. Inflammation-associated genes
US6340681B1 (en) 1999-07-16 2002-01-22 Pfizer Inc 2-benzimidazolylamine compounds as ORL-1-receptor agonists
CA2458533C (en) * 2001-10-09 2011-01-04 Tularik Inc. Imidazole derivates as anti-inflammatory agents
EP1448199A1 (en) * 2001-11-09 2004-08-25 Boehringer Ingelheim Pharmaceuticals Inc. Benzimidazoles useful as protein kinase inhibitors
WO2004014905A1 (en) * 2002-08-08 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzimidazole compounds
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
WO2007022305A2 (en) 2005-08-16 2007-02-22 Pharmacopeia, Inc. 2-aminoimidazopyridines for treating neurodegenerative diseases
WO2009143389A1 (en) 2008-05-21 2009-11-26 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
WO2010030857A2 (en) 2008-09-11 2010-03-18 The Regents Of The University Of Colorado Egfr inhibitor therapy responsiveness
JP2013512952A (ja) 2009-12-07 2013-04-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング インドールコアを含有する複素環化合物
CN102134275B (zh) 2010-01-26 2013-12-04 上海市肿瘤研究所 表皮生长因子受体变异体
WO2011099832A2 (en) 2010-02-12 2011-08-18 Crystalgenomics, Inc. Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
WO2012012016A1 (en) * 2010-07-20 2012-01-26 Miller Chemical & Fertilizer Corporation Compositions and methods for anti-icing/de-icing
WO2012018668A1 (en) 2010-08-05 2012-02-09 Amgen Inc. Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase
MX2014005632A (es) 2011-11-14 2014-10-17 Tesaro Inc Modulacion de ciertas cinasas de tirosina.
EP2890691B1 (en) 2012-08-31 2018-04-25 Principia Biopharma Inc. Benzimidazole derivatives as itk inhibitors

Also Published As

Publication number Publication date
JP2015518894A (ja) 2015-07-06
IL235974A0 (en) 2015-02-01
PL2773635T3 (pl) 2018-01-31
AU2013271733A1 (en) 2014-11-20
AP3909A (en) 2016-11-24
DK2773635T3 (da) 2017-11-06
UA113543C2 (xx) 2017-02-10
CA2875966A1 (en) 2013-12-12
BR112014030386A2 (pt) 2017-06-27
CN104379575A (zh) 2015-02-25
BR112014030386A8 (pt) 2021-09-28
PT2773635T (pt) 2017-09-26
EA201492219A1 (ru) 2015-05-29
JO3300B1 (ar) 2018-09-16
HRP20171670T1 (hr) 2017-12-15
EP2773635B1 (en) 2017-08-02
TWI650319B (zh) 2019-02-11
IL235974A (en) 2016-11-30
ES2645973T3 (es) 2017-12-11
EP2773635A1 (en) 2014-09-10
TW201350476A (zh) 2013-12-16
MX2014014961A (es) 2015-07-17
CL2014003227A1 (es) 2015-02-06
AP2014008083A0 (en) 2014-11-30
CN104379575B (zh) 2018-04-17
CO7160047A2 (es) 2015-01-15
EA026269B1 (ru) 2017-03-31
BR112014030386B1 (pt) 2022-09-27
MY165036A (en) 2018-02-28
AU2013271733B2 (en) 2017-02-16
GEP201606555B (en) 2016-10-10
UY34849A (es) 2014-01-31
GT201400282A (es) 2015-06-02
TN2014000487A1 (en) 2016-03-30
MA37739A1 (fr) 2018-09-28
LT2773635T (lt) 2017-10-10
PH12014502704B1 (en) 2015-02-02
KR20150023555A (ko) 2015-03-05
CA2875966C (en) 2019-02-26
MX345630B (es) 2017-02-08
JP6039800B2 (ja) 2016-12-07
US20150197505A1 (en) 2015-07-16
CR20140563A (es) 2015-01-16
HUE034759T2 (en) 2018-02-28
EP3257848A1 (en) 2017-12-20
KR101817829B1 (ko) 2018-01-11
DOP2014000277A (es) 2015-03-15
WO2013184757A1 (en) 2013-12-12
AR091368A1 (es) 2015-01-28
SI2773635T1 (sl) 2017-11-30
CU20140139A7 (es) 2015-04-29
US9440957B2 (en) 2016-09-13
CY1119531T1 (el) 2018-03-07
NZ627661A (en) 2016-02-26
PE20150726A1 (es) 2015-05-17
SG11201407793TA (en) 2014-12-30
MA37739B1 (fr) 2018-10-31
RS56396B1 (sr) 2017-12-29

Similar Documents

Publication Publication Date Title
PH12014502704A1 (en) Compounds and compositions for modulating egfr activity
MX2022011699A (es) Compuestos para tratar la atrofia muscular espinal.
MX357834B (es) Compuestos de tipo isocumarina sustituidos para tratar la atrofia muscular espinal.
MX352962B (es) Compuestos para tratar atrofia muscular espinal.
MX2015012478A (es) Metodos y composiciones para inhibicion de proteinas que contienen bromodominio.
PH12014501653A1 (en) Metalloenzyme inhibitor compounds
MX2015003874A (es) Modulacion de ire1.
IN2015DN00127A (enExample)
IN2015DN00598A (enExample)
PH12014502032A1 (en) Treatment of brain cancer
MX370253B (es) Composiciones de compuestos de jasmonato y métodos de uso de las mismas.
MX2016004540A (es) Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda).
IN2014CN04050A (enExample)
EA026371B8 (ru) Индолкарбонитрилы в качестве модуляторов рецептора андрогенов
WO2012017321A3 (en) Treatment for dyslipidemia
HK1222848A1 (zh) 用作alk抑制剂的吡咯并三嗪
IN2014DN06738A (enExample)
MX2013014488A (es) Metodos y composiciones para tratar el cancer cerebral.
MY165088A (en) Pharmaceutical compositions comprising alisporivir
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
UA105703C2 (uk) 7-бром-5-феніл-3-ариламіно-1,2-дигідро-3н-1,4-бенздіазепін-2-они як анальгетичні агенти
IN2015KN00386A (enExample)
IN2013CH00453A (enExample)
NI201400145A (es) Compuestos y composiciones que modulan la actividad del receptor del factor de crecimiento epidérmico
UA80618U (en) Use of n-steroylethanolamine as radiomodifier